0001683168-23-004086.txt : 20230713 0001683168-23-004086.hdr.sgml : 20230713 20230612193349 ACCESSION NUMBER: 0001683168-23-004086 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Coeptis Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001759186 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 981465952 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 105 BRADFORD ROAD, SUITE 420 CITY: WEXFORD STATE: PA ZIP: 15090 BUSINESS PHONE: 724-934-6467 MAIL ADDRESS: STREET 1: 105 BRADFORD ROAD, SUITE 420 CITY: WEXFORD STATE: PA ZIP: 15090 FORMER COMPANY: FORMER CONFORMED NAME: Bull Horn Holdings Corp. DATE OF NAME CHANGE: 20181115 CORRESP 1 filename1.htm

Coeptis Therapeutics Holdings, Inc.

105 Bradford Rd, Suite 420

Wexford, Pennsylvania 15090

June 12, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Timothy Buchmiller

	Re:	Coeptis Therapeutics Holdings, Inc.
		Registration Statement on Form S-1
		File No. 333-260782

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Coeptis Therapeutics Holdings, Inc. (the “Company”) respectfully requests that the effective date of the Registration Statement referred to above be accelerated so that it will become effective at 4:30p.m. Eastern Time, on, June 13, 2023, at 5:30 p.m., or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Please notify Denis Dufresne of Meister Seelig & Fein PLLC, counsel to the Company at (212) 655-3548 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

Thank you for your assistance in this matter.

	Very truly yours,

	COEPTIS THERAPEUTICS HODINGS, Inc.

	By:	/s/ David Mehalick
	Name:	David Mehalick
	Title:	Chief Executive Officer